Targeted inhibition of SCF-SKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma https://www.biorxiv.org/content/10.1101/2023.05.13.540637v1?med=mas
Targeted inhibition of SCF-SKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma https://www.biorxiv.org/content/10.1101/2023.05.13.540637v1?med=mas